Allopurinol 100mg tablets

Երկիր: Միացյալ Թագավորություն

Լեզու: անգլերեն

Աղբյուրը: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ակտիվ բաղադրիչ:

Allopurinol

Հասանելի է:

Accord-UK Ltd

ATC կոդը:

M04AA01

INN (Միջազգային անվանումը):

Allopurinol

Դոզան:

100mg

Դեղագործական ձեւ:

Oral tablet

Կառավարման երթուղին:

Oral

Դաս:

No Controlled Drug Status

Ռեկվիզորի տեսակը:

Valid as a prescribable product

Ապրանքի ամփոփագիր:

BNF: 10010400; GTIN: 5060149310366

Տեղեկատվական թերթիկ

* Please note that ONLY Artwork Studio is permitted to make changes to
the above artwork.
No changes are permitted by any 3rd party other than added notes and
mark ups for required changes.
approved for print/date
PROOF ROUND
Technical
Approval
NON PRINTING COLOURS
COLOURS
DATE SENT:
DATE RECEIVED:
Item number:
ORIGINATOR:
ORIGINATION DATE:
REVISION DATE:
REVISED BY:
DIMENSIONS:
MIN BODY TEXT SIZE:
SUPPLIER:
1.
2.
3.
4.
5.
6.
1.
2.
3.
[e-mail]
ALLOPURINOL 100MG & 300MG TABLETS PIL (REEL FED) - UK
Black
Profile
BBBB3518
S.Anson
15.12.2021
350 x 275
9pts
Accord Fawdon
n/a
n/a
1
Version 7
12.02.2020
German GTIN 14
(incorporating PZN):
Cartons and label leaflets only
(labels only when specified)
Front side
Back side
V3
BBBB3518
UKP002
0000000000
PACKAGE LEAFLET:
INFORMATION FOR THE USER
ALLOPURINOL 100MG AND
300MG TABLETS
(Allopurinol)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE
YOU START TAKING THIS MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
• Keep this leaflet. You may need to read it
again.
• If you have any further questions, ask your
doctor or pharmacist.
• This medicine has been prescribed for you
only. Do not pass it on to others. It may harm
them, even if their symptoms are the same as
yours.
• If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1. What Allopurinol Tablets are and what are
they used for
2. What you need to know before you take
Allopurinol Tablets
3. How to take Allopurinol Tablets
4. Possible side effects
5. How to store Allopurinol Tablets
6. Contents of the pack and other information
1. WHAT ALLOPURINOL TABLETS ARE
AND WHAT ARE THEY USED FOR
Allopurinol belongs to a group of medicines
called enzyme inhibitors. These medicines
inhibit the amount of uric acid production in your
body.
Allopurinol works by slowing down the speed of
certain chemical reactions in your body to lower
the level of uric acid in the blood and uri

Ապրանքի հատկությունները

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Allopurinol 100mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Allopurinol 100mg.
Excipients with known effect:
Each 100 mg tablet contains 34.765 mg of lactose monohydrate
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
White to off white, round, biconvex, uncoated tablet with inscription
"AW" on one
side and plain on the other side
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Allopurinol is indicated for reducing urate/uric acid formation in
conditions
where urate/uric acid deposition has already occurred (e.g. gouty
arthritis, skin
tophi, nephrolithiasis) or is a predictable clinical risk (e.g.
treatment of
malignancy potentially leading to acute uric acid nephropathy). The
main
clinical conditions where urate/uric acid deposition may occur are:
idiopathic
gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic
disease and
myeloproliferative disease with high cell turnover rates, in which
high urate
levels occur either spontaneously, or after cytotoxic therapy; certain
enzyme
disorders which lead to overproduction of urate, for example:
hypoxanthine-
guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome;
glucose-6-phosphatase including glycogen storage disease;
phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate
amidotransferase; adenine phosphoribosyltransferase. Allopurinol is
indicated
for management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related
to
deficient activity of adenine phosphoribosyltransferase.
Allopurinol is indicated for the management of recurrent mixed calcium
oxalate renal stones in the presence of hyperuricosuria, when fluid,
dietary and
similar measures have failed.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_ _
_POSOLOGY _
_ _
Allopurinol should be introduced at low dosage, e.g. 100 mg/day, to
reduce
the risk of adverse reactions and increased only if the serum urate
response is
unsatisfactory. Extra caution should be exe